NASDAQ:BNTC Benitec Biopharma Q4 2026 Earnings Results & Report $8.29 -0.34 (-3.94%) Closing price 10/14/2026 04:00 PM EasternExtended Trading$8.28 -0.01 (-0.12%) As of 10/14/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Benitec Biopharma beat analyst earnings expectations in its Q4 2026 results, released September 14, 2026. The company reported EPS of -$0.26 versus the -$0.2643 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2026Report DateSeptember 14, 2026TimeAfter Market ClosesConference Call4:00 PM ET Benitec Biopharma EPS ResultsActual EPS-$0.26Consensus EPS -$0.2643Beat/MissBeat by +$0.0043One Year Ago EPSN/AEPS Beat Rate5 of last 8 quartersBenitec Biopharma Revenue ResultsActual RevenueN/AExpected Revenue$13.70 millionBeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsBenitec Biopharma's Q1 2027 earnings is estimated for Friday, November 13, 2026, based on past reporting schedules, with a conference call scheduled at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Benitec Biopharma Q4 2026 Earnings FAQ Did Benitec Biopharma beat earnings estimates for Q4 2026? Benitec Biopharma (NASDAQ:BNTC) reported earnings of -$0.26 per share for Q4 2026, beating the consensus estimate of -$0.2643. The report was announced on Monday, September 14, 2026. When is Benitec Biopharma's next earnings date? Benitec Biopharma's next earnings date is estimated for Friday, November 13, 2026. MarketBeat tracks confirmed and estimated earnings dates for Benitec Biopharma on the company's earnings history page. Benitec Biopharma Earnings HeadlinesBenitec Biopharma Limited (NASDAQ:BNTC) Stock Has Consensus Target Price of $24.00 According to BrokeragesOctober 11, 2026 | americanbankingnews.comBenitec Biopharma Announces Regulatory Update Following Type C Meeting with FDA for BB-301 Pivotal StudyOctober 5, 2026 | globenewswire.comSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from collapsing — and billionaire Sam Altman is now an investor. This under-the-radar firm is drawing serious attention from those watching the energy infrastructure space closely.October 15 at 1:00 AM | Altimetry (Ad)Analysts Offer Insights on Healthcare Companies: Benitec Biopharma (BNTC), CVS Health (CVS) and BioNTech SE (BNTX)September 16, 2026 | theglobeandmail.comWedbush Lifts Price Target on Benitec Biopharma to $17 From $16, Keeps Outperform RatingSeptember 15, 2026 | finance.yahoo.comBenitec Biopharma Files $200 Million Shelf RegistrationSeptember 15, 2026 | finance.yahoo.comSee More Benitec Biopharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Benitec Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Benitec Biopharma and other key companies, straight to your email. Email Address About Benitec BiopharmaBenitec Biopharma (NASDAQ:BNTC) (NASDAQ:BNTC) is a clinical-stage biotechnology company developing genetic medicines for chronic and potentially life-threatening diseases. The company’s work is based on DNA-directed RNA interference (ddRNAi), a gene-silencing technology designed to produce sustained suppression of disease-causing genes within targeted cells. Benitec’s lead investigational product is BB-301, an adeno-associated virus gene therapy being developed for oculopharyngeal muscular dystrophy (OPMD), a rare inherited disorder that can cause progressive difficulty swallowing and weakness of the eyelid and throat muscles. BB-301 is designed to silence the mutated PABPN1 gene associated with OPMD while supporting production of a functional version of the gene. Founded in Australia in 1995, Benitec has developed its technology through research, licensing, and clinical-development activities and now operates as a U.S.-based biotechnology company. Its activities are focused primarily on advancing its gene-therapy pipeline through clinical studies and regulatory development rather than marketing commercial products.View Benitec Biopharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Citi Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenIREN Limited's AI Pivot Gains Traction—But Can Its Data Centers Deliver?PBF Energy's Stunning Rally Faces a Critical TestA Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Albertsons Is Betting on a Turnaround—But Will It Pay Off?PepsiCo's Earnings Beat Masks a Bigger Problem With Its North American Business Upcoming Earnings Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026)ICICI Bank (10/17/2026)America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
